Literature DB >> 2083147

Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers.

A Avgerinos1, A J Hutt.   

Abstract

The plasma disposition of the enantiomers of ibuprofen has been investigated following the oral administration of the racemic drug (400 mg) to 24 healthy male volunteers. The plasma elimination of (R)-ibuprofen was found to be more rapid than that of the S-enantiomer [plasma half-life: (R) 2.03 h; (S) 3.05 h; 2P less than 0.001], resulting in a progressive enrichment in the plasma content of this isomer, some 64% of the total area under the plasma concentration time curves (AUC) being due to the pharmacologically active enantiomer. The influence of dose on the pharmacokinetic characteristics of the enantiomers of ibuprofen, over the range 200-800 mg, was investigated in three subjects. Examination of dose-normalized AUC values and oral clearance indicate the dose dependence of (R)-ibuprofen disposition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083147     DOI: 10.1002/chir.530020410

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  9 in total

1.  Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.

Authors:  Ville-Veikko Hynninen; Klaus T Olkkola; Kari Leino; Stefan Lundgren; Pertti J Neuvonen; Anders Rane; Mika Valtonen; Hanna Vyyryläinen; Kari Laine
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 2.  Drug chirality and its clinical significance.

Authors:  A J Hutt; S C Tan
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  Drugs of environmental concern modify Solea senegalensis physiology and biochemistry in a temperature-dependent manner.

Authors:  A González-Mira; I Varó; M Solé; A Torreblanca
Journal:  Environ Sci Pollut Res Int       Date:  2016-08-03       Impact factor: 4.223

Review 4.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 5.  Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety.

Authors:  Nicholas Moore
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 6.  Pharmacokinetic optimisation of the treatment of osteoarthritis.

Authors:  K J Skeith; D R Brocks
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

7.  Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis.

Authors:  G Geisslinger; K P Stock; D Loew; G L Bach; K Brune
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

8.  Comparison of the bioavailability of dexibuprofen administered alone or as part of racemic ibuprofen.

Authors:  B Gabard; G Nirnberger; H Schiel; H Mascher; C Kikuta; J M Mayer
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 9.  Enantiospecific analysis: applications in bioanalysis and metabolism.

Authors:  A J Hutt; M R Hadley; S C Tan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.